Dr Amol Akhade

Happy to share our article in lancet oncology about Accelerated pathway ( mis ) use in oncology drug approval and differential treatment given by pharma giants to LMIC , while withdrawing cancer drugs. Thank you @oncology_bg @SirohiBhawna for being with me for this efforts .

Hi ALL Did one new experiment on oncology social media 🙂 Made my account on Substack and uploaded my article on it 👇 If you find it useful, DO share or subscribe and comment 🙂. open.substack.com/pub/dramolakha…

🆕 Mini Review: Mesonephric Carcinoma and Mesonephric-like Adenocarcinoma of the Female Genital Tract ✍️ Authors: Yanjun Hou, Deyin Xing and Zaibo Li 🔗 Read more: xiahepublishing.com/2771-165X/JCTP… 👥 @gcai1978 @CAPA_comm @SuyogCancer #Mesonephric

Several TKIs can inhibit OCT2 and MATE1, leading to elevated serum creatinine levels without affecting the GFR, a phenomenon known as pseudo-acute kidney injury. Sharing our correspondence regarding the same @JCO_ASCO #oncmeded #lcsm ascopubs.org/doi/10.1200/JC…

For all Those who ask me , Does Mobile Phone use increases risk of cancer? Answer is NO.

Treatment Algorithm: This is the algorithm we have used during our discussion w/ @Anand_88_Patel for AML! #OncTwitter #MedTwitter #HemeTwitter @OncUpdates

We appreciate the feedback on the table we had shared! Made some changes based on the recs/step-up dosing for Epcoritamab (as we also need this for Glofit) 🙏🏽🙏🏽! Here is the updated version 👇👇 #HemeTwitter #OncTwitter #MedTwitter #ChallengingCases

For all those who ask me about If sugar intake causes cancer ? #CancerAwareness #mythsvsfact

In this discussion of “Challenging Cases” with @DrCarlaCasulo & #DrTaraGraff, we had a chance to touch on our options in R/R DLBCL: Epcoritamab, Glofitamab, and LoncaT! Here is the table/studies that got these drugs approved. #HemeTwitter #MedTwitter #OncTwitter

🔥New series: “Challenging Cases” from the community. Starting off with treatment options in R/R DLBCL with focus on bi-specific antibodies with @DrCarlaCasulo & #DrTaraGraff Full discussion: ⭐️ oncbrothers.com/cases-dlbcl-20… ⭐️ Also on the “Oncology Brothers” podcast #HemeTwitter

🚨 Big news in #lungcancer! 📢 Final OS data from FLAURA2 💊 Tagrisso + chemo ⬆️ overall survival in 1L EGFRm NSCLC vs Tagrisso alone 🔑 Statistically & clinically meaningful 🧬 Longest median PFS in class 🛡 No restriction on post-progression Rx . It will be intresting to see…

✍️ Writing is thinking. 👉🏼A powerful editorial in Nature Reviews Bioengineering (Vol. 3, p. 431, 2025) reminds us of something timeless: in science, writing is far more than reporting results. It’s a way of sharpening thought. 👉🏼Even in an age shaped by large-language models,…

👏This review summarizes 5️⃣ years of progress in transarterial intervention + systemic therapy for hepatocellular carcinoma (#HCC). @DrAngelaLamarca @ArndtVogel @SuyogCancer @rachnatshroff @MikeChuongMD @KrishanJethwa @dr_yakupergun @Amitmahipal79 @pashtoonkasi @NiuSanford

🚨 MET in Cancer: Mutation, Amplification & Resistance 🧬 MET is a key oncogenic driver—especially in NSCLC, HCC, gastric & RCC. But resistance is smart. It strikes via: 1️⃣ On-target MET mutations (e.g., D1228N, Y1230C/S/H) 2️⃣ Downstream rewiring (KRAS, BRAF, PI3K, PTEN, MYC) 3️⃣…

Not to mention submission fees & journal paywalls decrease accessibility. Plus, usually major time delay from submission to publication. I think in past there was prestige associated with getting LTE accepted by high impact journal, which may still be the case but less so. All…

Usually LTE are critical of the study/decision of editors to publish it. So it seems to be COI that the same editor has to then approve the LTE...makes sense they might not want to publicize they overlooked some issue with study methodology, conclusion, etc.

Only 9 % of voters believe that letter to editor will generate discussion for the critical points raised in published clinical trials . Vote 👇 below.

What u think of this ? 🙂👇

I worry that the majority of that benefit is being driven by BRCA and PLAB2. Is this going to be your 1L for all HRRm? @neerajaiims @DrRanaMcKay @dr_yakupergun PARPi have a good amount of side effects with very little benefit with certain HRR deficiencies. Love this slide by…

Want to raise a critical point on a published clinical trial? 🧪 What actually works to reach right people and spark discussion? 🤔 1️⃣ Letter to the Editor – 95% desk rejection 📄🗑️ (especially if it's a sponsored trial…🤫) 2️⃣ Post on X or LinkedIn – wider audience, real…

Most of the time, X✌️; rarely, a letter to the editor to a journal. Sometimes it feels like your manuscript’s fate depends less on its content and more on whether the editor had a good cup of coffee that morning. Worse still, you might share a fresh perspective, get a polite…